How Eli Lilly’s Cardiovascular Products Performed in 4Q17



Cardiovascular products

Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment also includes the cardiovascular products Adcirca, Cialis, Effient, and Reopro. Cialis, Effient, and Reopro reported revenue falls in 4Q17. Adcirca’s revenue rise marginally offset this fall in the quarter.

The chart above shows the revenues of Cialis and Effient since 1Q16.

Article continues below advertisement


Cialis is a blockbuster drug from Eli Lilly’s cardiovascular portfolio. Cialis is approved for the treatment of erectile dysfunction and benign prostatic hyperplasia. Cialis reported a 12% fall in revenue to $597.4 million in 4Q17 compared to $676.3 million in 4Q16. The fall was driven by lower sales of Cialis in both US and international markets. The drug’s US sales fell ~12.7%, and its international sales fell ~10.1% due to increased competition.


Effient is an antiplatelet approved for the prevention of blood clots in arteries and stents, thereby reducing the chances of heart issues. It’s been approved for use in combination with aspirins. Effient is part of Eli Lilly’s collaboration with Daiichi Sankyo Company. Eli Lilly holds marketing rights for the drug in US markets, while Daiichi Sankyo holds its marketing rights in Europe and Japan. Effient reported a 56% fall in revenue to $62.3 million in 4Q17 from $140.9 million in 4Q16.

Other drugs

Adcirca and Reopro are other cardiovascular products from Eli Lilly. Adcirca’s revenue rose to $24.4 million in 4Q17 compared to $18.2 million in 4Q16. Reopro reported revenue of $0.3 million in 4Q17.

The iShares Global Healthcare ETF (IXJ) holds 1.6% of its total investments in Eli Lilly, 2.0% in Sanofi (SNY), 2.3% in Abbott Laboratories (ABT), and 2.6% in Amgen (AMGN).


More From Market Realist